Venous and arterial thromboembolic diseases are still the most frequent causes of death and disability in high-income countries. Clinical anticoagulants are inhibitors of enzymes involved in the coagulation pathway, such as thrombin and factor X a. Thrombin is a key enzyme of blood coagulation system, activating the platelets, converting the fibrinogen to the fibrin net, and amplifying its self-generation by the activation of factors V, VIII, and XI. Thrombin has long been a target for the development of oral anticoagulants. Furthermore, selective inhibitors of thrombin represent a new class of antithrombotic agents. For these reasons, a number of specific thrombin inhibitors are under evaluation for possible use as antithrombotic drugs. This paper summarizes old and new interests of specific thrombin inhibitors described in different animals. Copyright © 2010 A. M. Tanaka-Azevedo et al.
CITATION STYLE
Tanaka-Azevedo, A. M., Morais-Zani, K., Torquato, R. J. S., & Tanaka, A. S. (2010). Thrombin inhibitors from different animals. Journal of Biomedicine and Biotechnology. https://doi.org/10.1155/2010/641025
Mendeley helps you to discover research relevant for your work.